DEALS: Novartis angling for Chiron buyout

DEALS

WHO

WITH

WHAT

SCOOP

Novartis

Chiron

$4.5 billion buyout

Chiron wants more than what Novartis is offering for all the shares it doesn't already own, and analysts think the troubled vaccine maker may just get it.

GlaxoSmithKline

ID Biomedical

$1.4 billion buyout

The deal boosts GSK's role in the flu vaccine business.

Caliper Life Sciences

NovaScreen Biosciences

$22 million buyout

Caliper says the acquisition adds screening, profiling and assay development services, helping make the company a central resource for drug developers.

Barr Pharmaceuticals

Organon

Acquisition of oral contraceptive Mircette

The drug buy paves the way to settle patent litigation surrounding the contraceptive.

Actavis Group

Higia AD

Buyout

Higia is one of the largest drug distributors in Bulgaria.